Australia Pharmaceutical Market Size & Outlook, 2025-2030
Related Markets
Australia pharmaceutical market highlights
- The Australia pharmaceutical market generated a revenue of USD 34,289.6 million in 2024 and is expected to reach USD 50,997.9 million by 2030.
- The Australia market is expected to grow at a CAGR of 6.8% from 2025 to 2030.
- In terms of segment, conventional drugs (small molecules) was the largest revenue generating molecule in 2024.
- Biologics & Biosimilars (Large Molecules) is the most lucrative molecule segment registering the fastest growth during the forecast period.
Pharmaceutical market data book summary
| Market revenue in 2024 | USD 34,289.6 million |
| Market revenue in 2030 | USD 50,997.9 million |
| Growth rate | 6.8% (CAGR from 2025 to 2030) |
| Largest segment | Conventional drugs (small molecules) |
| Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
| Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Australia accounted for 2.1% of the global pharmaceutical market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China pharmaceutical market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 63,747.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pharmaceutical Market Scope
Pharmaceutical Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Australia pharmaceutical market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 57.97% in 2024. Horizon Databook has segmented the Australia pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
Australia’s pharmaceutical market is driven by a combination of strong government support, a growing aging population, rising chronic disease prevalence, and a robust research and development (R&D) ecosystem.
These factors, along with the country’s increasing demand for innovative medicines and generics, make Australia an attractive destination for pharmaceutical investments. A key driver of Australia’s pharmaceutical market is its universal healthcare system, Medicare, which ensures affordable access to essential medicines.
The Pharmaceutical Benefits Scheme (PBS) plays a crucial role by subsidizing prescription drugs, making treatments more accessible and reducing out-ofpocket expenses for patients. This system fosters a stable demand for pharmaceuticals, particularly for chronic disease management and elderly care.
Reasons to subscribe to Australia pharmaceutical market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia pharmaceutical market databook
-
Our clientele includes a mix of pharmaceutical market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into Australia pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia pharmaceutical market size, by molecule, 2018-2030 (US$M)
Australia Pharmaceutical Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
No records
No related industry reports found.
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
